Want to see HK:2257 full AI Analyst Report?
2257 Stock Chart & Stats
HK$8.00
-HK$0.09(-2.79%)
At close: 4:00 PM EST
HK$8.00
-HK$0.09(-2.79%)
Day’s Range― - ―
52-Week RangeHK$3.76 - HK$22.78
Previous CloseN/A
Volume36.40K
Average Volume (3M)442.62K
Market Cap
HK$501.43M
Enterprise ValueHK$65.29M
Total Cash (Recent Filing)HK$13.52M
Total Debt (Recent Filing)HK$9.31M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding109,721,535
10 Day Avg. Volume408,789
30 Day Avg. Volume442,620
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-9.39
Price to Sales (P/S)0.00
P/FCF Ratio-10.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)HK$162.00M
Bulls Say, Bears Say
Bulls Say
Platform And Delivery ExpertiseSirnaomics' core RNAi therapeutic platform and in-house delivery technology represent durable scientific assets. Successful delivery is a high barrier in oligonucleotide therapeutics, so sustained R&D capability can translate into long-term competitive advantage and multi-program optionality across oncology and other indications.
Materially Smaller Net Loss In 2025A materially smaller net loss in 2025 indicates improved cost control or operational efficiency. If sustained, this demonstrates management execution on expense discipline and lowers the pace of runway depletion, improving the company's ability to advance programs without immediate dilutive financing.
Improving Cash Burn TrendThe marked improvement in cash burn across 2024–2025 points to better cash management and potential operational scaling. Reduced cash outflows extend runway and enhance optionality for financing or partnerships, making the firm more resilient while it progresses clinical programs.
Bears Say
Negative Shareholder EquityTransition to negative shareholder equity is a structural weakness that reduces financial flexibility and raises refinancing and dilution risk. Negative equity complicates borrowing and can force dilutive capital raises, weakening long-term solvency and the firm's ability to fund R&D without adverse terms.
Revenue Fell To Zero In 2025A return to zero revenue underscores the absence of commercialized products and limited scale. Lack of recurring sales means the company cannot self-fund development, increasing reliance on external capital and making long-term program advancement contingent on financing or partner deals.
Persistent Negative Operating And Free Cash FlowConsistent negative operating and free cash flow require ongoing capital raises and heighten dilution risk. Despite burn improvement, persistent cash deficits limit strategic flexibility, increase financing dependence, and may delay or curtail development timelines if funding conditions deteriorate.
Sirnaomics Ltd. News
2257 FAQ
What was Sirnaomics Ltd.’s price range in the past 12 months?
Sirnaomics Ltd. lowest stock price was HK$3.76 and its highest was HK$22.78 in the past 12 months.
What is Sirnaomics Ltd.’s market cap?
Sirnaomics Ltd.’s market cap is HK$501.43M.
When is Sirnaomics Ltd.’s upcoming earnings report date?
Sirnaomics Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 45 days.
How were Sirnaomics Ltd.’s earnings last quarter?
Sirnaomics Ltd. released its earnings results on Mar 27, 2026. The company reported -HK$0.881 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.881.
Is Sirnaomics Ltd. overvalued?
According to Wall Street analysts Sirnaomics Ltd.’s price is currently Overvalued.
Does Sirnaomics Ltd. pay dividends?
Sirnaomics Ltd. does not currently pay dividends.
What is Sirnaomics Ltd.’s EPS estimate?
Sirnaomics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sirnaomics Ltd. have?
Sirnaomics Ltd. has 109,721,535 shares outstanding.
What happened to Sirnaomics Ltd.’s price movement after its last earnings report?
Sirnaomics Ltd. reported an EPS of -HK$0.881 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.516%.
Which hedge fund is a major shareholder of Sirnaomics Ltd.?
Currently, no hedge funds are holding shares in HK:2257
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sirnaomics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
207.69%
12-Months-Change
Fundamentals
Return on Equity
191.92%
Trailing 12-Months
Asset Growth
-27.12%
Trailing 12-Months
Company Description
Sirnaomics Ltd.
Sirnaomics Ltd. is an RNA therapeutics biopharmaceutical company, founded in 2007 and headquartered in Gaithersburg, Maryland. The company is dedicated to identifying and developing innovative therapeutic compounds aimed at addressing significant medical needs across the United States and the People's Republic of China. Its leading pipeline assets include STP705, which is being investigated for conditions such as cutaneous squamous cell carcinoma in situ, basal cell carcinoma, various liver-related cancers (cholangiocarcinoma, hepatocellular carcinoma, liver metastases), as well as for keloid scar remodeling, hypertrophic scarring, and fat sculpting. Another prominent candidate, STP707, is designed to treat cholangiocarcinoma, hepatocellular carcinoma, liver metastases, metastatic cutaneous squamous cell carcinoma, non-small cell lung cancer, and both liver and lung fibrosis. Beyond these lead programs, Sirnaomics is advancing STP355 for a range of cancers; STP369 for head and neck/bladder cancers; STP779 for liver, lung, and pancreatic cancers; and STP902 for breast cancer. The company's portfolio also extends to infectious diseases with STP702 for influenza, STP908 for COVID-19, the RIM730 COVID-19 vaccine, and STP909 for HPV/cervical cancer. Furthermore, its developmental pipeline encompasses STP122G for thrombotic disorders, STP125G for hypertriglyceridemia, STP144G for complement-mediated ailments, STP133G for cardiometabolic conditions, and STP155G for hepatitis B virus.
Technical Analysis
Alphamab Oncology
―
Jacobio Pharmaceuticals Group Co., Ltd.
―
CARsgen Therapeutics Holdings Ltd.
―
Transcenta Holding Limited
―
Ascentage Pharma Group International
―